Despite the wide use of dopamine receptor blocking agents (DRBAs) in Huntington disease (HD), neuroleptic malignant syndrome (NMS) is rarely described in this population. The aim of this study was… Click to show full abstract
Despite the wide use of dopamine receptor blocking agents (DRBAs) in Huntington disease (HD), neuroleptic malignant syndrome (NMS) is rarely described in this population. The aim of this study was to assess NMS prevalence in a large cohort of HD patients and explore the main associated risk factors.
Keywords:
disease neuroleptic;
malignant syndrome;
huntington disease;
neuroleptic malignant
Journal Title: European Journal of Neurology
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Neurology
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!